flaccidoxide-13-acetate

Flaccidoxide-13-acetate is a **marine-derived sesquiterpenoid compound** isolated from the soft coral *Cladiella kashmani*, classified as a prenol lipid. It has demonstrated **antitumor activity**, notably in human hepatocellular carcinoma (HCC) and bladder cancer cell lines. The compound exerts **cytotoxic effects** via inhibition of cell viability, migration, and invasion, and induces **apoptosis** through mitochondrial dysfunction, upregulation of pro-apoptotic proteins (Bax, Bad), cytochrome c release, and activation of caspase 9 and caspase 3. Its mechanism involves **suppression of matrix metalloproteinases (MMP-2, MMP-9, MMP-13), urokinase plasminogen activator (uPA)**, and upregulation of tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2). Flaccidoxide-13-acetate also disrupts the **focal adhesion kinase (FAK)/PI3K/Akt/mTOR signaling pathway** and impairs **epithelial-to-mesenchymal transition (EMT)** via downregulation of Snail, N-cadherin, vimentin, and β-catenin. Preclinical studies support its potential as a candidate for development as an **anticancer agent targeting migration, invasion, and metastasis** in solid tumors, but further in vivo and clinical research is needed[1][3][5].

Other names

(1S,4E,8E,10Z,12R,13S,14R)-13-acetyloxy-4,8,14-trimethyl-11-propan-2-yl-15-oxabicyclo[12.1.0]pentadeca-4-en-15-one